Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 901 - 925 of 15308 in total
Infection with pathogenic filoviruses, such as Zaire ebolavirus (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as 90%.[A225933, A225938] Virtually all steps of the EBOV lifecycle have been targeted for therapeutic development. However, to date, the most successful...
Approved
Investigational
Matched Description: … to be superior, with improved patient survival and faster viral clearance rates. ... [maftivimab]), the now approved ansuvimab, and ZMapp, which remains in clinical trials. ... evidenced by the previously approved INMAZEB™ (REGN-EB3, a cocktail of [atoltivimab], [odesivimab], and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Ascorbyl phosphate is a synthetic form of Vitamin C and is found in different salt forms such as magnesium ascorbyl phosphate and sodium ascorbyl phosphate. These salts are present in cosmetic products at concentrations ranging from 0.001 % to 3% . As vitamin C is susceptible to breakdown of compound...
Approved
Matched Description: … ascorbyl phosphate and sodium ascorbyl phosphate. ... Ascorbyl phosphate is a synthetic form of Vitamin C and is found in different salt forms such as magnesium ... phosphate, along with other Vitamin C derivatives, acts as an active and stable precursor of vitamin …
Matched Categories: … Vitamin C and analogues …
A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.
Approved
Illicit
Matched Description: … A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …
Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus. Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was found to reduce the risk of...
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Melphalan flufenamide, also known as melflufen or J1, is a prodrug of melphalan.[A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases. In vitro models show that melphalan is 10 to hundreds of times more potent than melphalan. The increased...
Approved
Withdrawn
Matched Description: … [A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved ... which showed a decrease in overall survival in comparison to standard treatment with [pomalidomide] and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.
Approved
Matched Description: … infection and death caused by anthrax toxin. ... Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest. It is an extracellular plant cysteine proteinase similar to papain in specificity. Chymopapain was developed by Chart Medcl and FDA approved...
Approved
Withdrawn
Matched Description: … [A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. …
Matched Categories: … Enzymes and Coenzymes …
Certoparin is part of the heparins of low molecular weight that presents high activity against the coagulation factor Xa. It is normally used to prevent deep venous thrombosis.
Approved
Investigational
Matched Categories: … Heparin and similars …
Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by...
Approved
Investigational
Matched Description: … [A218186, L15526] In this manner, PMOs are much less susceptible to endo- and exonucleases and exhibit ... cardiac function and is invariably fatal. ... dystrophy known as Becker muscular dystrophy (BMD) is characterized by the production of shortened and
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains...
Approved
Investigational
Matched Description: … regions of the VH genes Cor (1) and Cess (2). ... Synagis is a composite of human (95%) and murine (5%) antibody sequences. ... 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF) …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
C1 Esterase Inhibitor (Recombinant) is a recombinant analogue of endogenous complement component-1 esterase inhibitor (rhC1INH), purified from the milk of transgenic rabbits. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways. It does this through inhibition of several target proteases within...
Approved
Investigational
Matched Description: … tPA and plasmin within the fibrinolytic pathway. ... Additionally, C4 and C2 cleavage occurs resulting in auto-activation of the complement system. ... The primary function of endogenous C1INH is to regulate the activation of the complement and contact …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Insulin beef has been discontinued in the US and Canada since 2017.
Approved
Matched Description: … Insulin beef has been discontinued in the US and Canada since 2017.[L10827] …
Matched Categories: … Alimentary Tract and Metabolism ... Insulins and Analogues for Injection, Fast-Acting …
A barbiturate that is metabolized to phenobarbital. It has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over phenobarbital.
Approved
Matched Categories: … Barbiturates and Derivatives ... Hypnotics and Sedatives ... Phenobarbital and similars …
Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated with narcolepsy or obstructive sleep apnea[FDA Label]. Solriamfetol was given FDA approval in 2019[FDA Label].
Approved
Matched Description: … Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Dopamine And Norepinephrine Reuptake Inhibitors ... Psychostimulants, Agents Used for ADHD and Nootropics …
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy...
Approved
Matched Description: … [A263071] Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of ... 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides. ... It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs Affecting Bone Structure and Mineralization …
Technetium Tc-99m nofetumomab merpentan (Tc-99m nm) consists of a Fab fragment of an IgG2b of the pancarcinoma murine antibody NR-LU-10. The NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and some normal tissues.[FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma...
Approved
Withdrawn
Matched Description: … [FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14 ... NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Vespula maculifrons venom protein is an extract of Vespula maculifrons venom. Vespula maculifrons venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …
Silver nitrate is an inorganic compound with the chemical formula AgNO3. In its solid form, silver nitrate is coordinated in a trigonal planar arrangement. It is often used as a precursor to other silver-containing compounds. It is used in making photographic films, and in laboratory setting as a staining agent...
Approved
Investigational
Matched Description: … in PAGE gels and in scanning electron microscopy. ... It is used in making photographic films, and in laboratory setting as a staining agent in protein visualization …
Matched Categories: … Antiseptics and Disinfectants …
Turoctocog alfa pegol is a pegylated version of turoctocog alfa. Novo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February 19, 2019. Fundamentally, the N8-GP moiety is identical to turoctocog alfa, a recombinant human clotting factor VIII (rFVIII) with a truncated B-domain made...
Approved
Matched Description: … It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104]. ... The essential difference between turoctocog alfa and N8-GP, however, is the specific attachment of a ... rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted...
Approved
Investigational
Matched Description: … Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour...
Approved
Investigational
Matched Description: … Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint ... unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and ... L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year,...
Approved
Investigational
Matched Description: … ] and Health Canada,[L48171] respectively. ... programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and ... [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126 …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4). It is a benzylisoquinoline derivative that is structurally related to papaverine, although it displays more potent antispasmodic activities than papaverine. Drotaverine has been used in the symptomatic treatment of various spastic conditions, such as gastrointestinal diseases, biliary dyskinesia, and...
Approved
Investigational
Matched Description: … [A7036] It also has been investigated in dysmenorrhea, abortion, [A231609] and augmentation of labour ... recently, drotaverine gained attention in the treatment of benign prostatic hyperplasia, parainfluenza, and ... symptomatic treatment of various spastic conditions, such as gastrointestinal diseases, biliary dyskinesia, and
Matched Categories: … Alimentary Tract and Metabolism ... Papaverine and Derivatives …
Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic...
Approved
Investigational
Matched Description: … [L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States ... genetic disorder in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and ... non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …
Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Approved
Investigational
Withdrawn
Matched Description: … ., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke …
Matched Categories: … Genito Urinary System and Sex Hormones ... Antiinflammatory and Antirheumatic Products ... Gynecological Antiinfectives and Antiseptics ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Displaying drugs 901 - 925 of 15308 in total